Key Highlights

● ResMed closed at $229.97 on 9 October 2026.

● Market data consensus target is $241.69 from 16 analysts.

● Targets range from $213.00 to $300.00.

● Royal Bank of Canada upgraded the shares.

On Friday 9 October 2026, ResMed (NYSE:RMD), a member of the S&P 500, closed at $229.97. The consensus target sits moderately above the share price.

What Is the Latest Analyst Price Target?

Market data shows a consensus price target of $241.69 from 16 analysts over the last 12 months. The highest target is $300.00, from UBS, and the lowest is $213.00, from Robert W. Baird. Against the $229.97 close, the consensus implies upside of about 5.1%, a much narrower gap than for many large-cap peers.

The second data set, using third-party data for 20 analysts, reports an average of $250.22, a median of $235, a high of $320 and a low of $175, implying about 8.8% upside.

Recent named targets support the lower end of that range. Nine broker targets published since July average about $240, close to the market data figure.

What Are Wall Street Analysts Saying?

Opinion is split. Market data records seven Buy and nine Hold ratings with no Sells, giving a Hold consensus. The second data set lists seven Strong Buy, two Buy, ten Hold and one Strong Sell rating, which it summarises as Buy.

On 15 September Royal Bank of Canada upgraded the shares from Sector Perform to Outperform and raised its target from $244 to $262. KeyCorp lifted its Overweight target from $255 to $267 on 31 August. Rothschild & Co Redburn initiated coverage at Neutral with a $230 target on 19 August. On 7 August, after the latest results, Piper Sandler lowered its target from $233 to $225, Wells Fargo from $225 to $215, and Baird set a $213 target. UBS reiterated its Buy rating with a $300 target on 21 July, while Mizuho and Jefferies both reduced targets in July. Citigroup maintained a Neutral rating on 10 September.

What Could Help the Stock Reach the Price Target?

For the quarter reported in early August 2026, market data cites earnings per share of $2.95 against a $2.89 consensus estimate and revenue of $1.46 billion, up 8.6% on a year earlier. Continued profit growth of that kind would support analysts who rate the shares Buy.

The upgrade from RBC and the higher KeyCorp target show that some brokers have become more positive since the summer. Because the consensus target is only about 5% above the share price, relatively modest progress could bring the shares close to it, though this is far from certain.

What Could Prevent the Stock Reaching the Target?

The stock fell sharply after its August results. Market data reports a gap down of 16.06% on 7 August 2026, and several brokers cut targets that day.

Analysts are also cautious. Nine of 16 ratings on market data are Hold, and the lowest target of $213 sits below the current price. The second data set includes a low target of $175, which implies a decline. A weaker outlook for the company or its sector could keep the shares below the consensus.

What Should Investors Watch Next?

Other points to follow include further broker upgrades or downgrades, whether broker sentiment continues to improve and any news affecting demand for the company's devices.

ResMed Versus Its Analyst Targets

ResMed closed at $229.97 on 9 October 2026, against a market data consensus target of $241.69. On 15 September Royal Bank of Canada upgraded the shares from Sector Perform to Outperform and raised its target from $244 to $262.